Navigation Links
Effectively Bringing Fixed Dose Combination Products to Market to Maintain Growth and Pipelines

CHAPEL HILL, N.C., March 8, 2013 /PRNewswire/ -- The pharmaceutical industry has turned to sustainable growth opportunities to address the pipeline and patent challenges facing many organizations in the sector. One opportunity for growth lies in extending a product's patent life by combining branded products.

Fixed dose combination (FDC) products have clinical and commercial advantages. For the drug manufacturer, an FDC product can extend the therapeutic advantage and becomes part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.

But there is more to success than just developing a new FDC and launching it. Successful research and development leaders recognize that understanding the market and audience will smooth the FDC launch process, according to a study by benchmarking leader Best Practices, LLC.

"Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market" identifies successful strategies and innovative practices for developing and bringing FDC products to market. Through executive insights and advice, the study also addresses the pitfalls and obstacles to avoid in this work.

A third of the FDC leaders who participated in the study said the most important lesson learned from their work with FDC products is the need to focus on the differentiated benefit and value that the product can bring to patients, physicians and payers.

Some of the issues addressed in this research include:

  • Chief reason for pursuing FDC development
  • Measures used to evaluate success
  • Years from decision to develop through launch
  • Cost of FDC product development
  • Time lapsed from initial contact to signed contractual agreement with partner
  • U.S. filing routes used
  • EU filing routes used
  • Lessons learned from executives
  • Metrics for effectively communicating business value

The full 55-page report contains more than 150 benchmark metrics, providing executives with the tools, tactics and techniques to help organizations successfully develop and commercialize fixed dose combination products.

Review a complimentary summary of the study at The summary includes selected best practices drawn from extensive primary research with 51 representatives from 34 leading companies, including eight of the Top 20 pharma companies. 

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ensuring Pharmaceutical Organizations are Effectively Organizing and Deploying Medical Science Liaisons across Diverse Customer Groups
2. Louisiana Pain Specialist Dr. Arnold Feldman Uses Advanced Techniques to Effectively Treat Herniated Disc
3. Effectively Using Communication Channels and Tools to Reach Core Decision Makers in Organizations Across all Business Sectors
4. Positioning Strategies Effectively Minimize Cannibalization of a Legacy Brand When Expanding a Product Portfolio
5. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
6. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
7. Clinical Site Services Is Bringing 3x More Patient Enrollment to the 48th Annual DIA Meeting
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 Sectra ... has entered into a multi-year agreement to deploy ... This investment will provide the Breast Center a future-proof ... Sectra (STO: SECT B) announces that Breast Center ... to deploy Breast Imaging PACS in its two freestanding ...
(Date:11/24/2015)... Mass. , Nov. 24, 2015   HeartWare ... innovator of less-invasive, miniaturized circulatory support technologies that are ... that President and Chief Executive Officer Doug Godshall ... 27 th Annual Healthcare Conference on December 1, ... held December 1-2 in New York ...
(Date:11/24/2015)... and BERN, Switzerland , ... the ARTORG Center for Biomedical Engineering Research of the ... the Division of Endocrinology, Diabetes and Clinical Nutrition of ... the start of an exclusive collaboration to develop a ... algorithm for the personalised delivery of insulin for diabetic ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating ... quality and cost of health care services available to its members to help ...
(Date:11/24/2015)... ... ... Rodney E. Willey , has answered a new calling – to relieve snoring and sleep ... snoring and sleep apnea through oral appliance therapy. He is one of ... US, one of four in the Illinois area. , Dr. Willey’s location is ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health ... have announced their endorsement of the Medical Fitness Network (MFN), a national ... to have the MFN as one of our endorsed organizations,” said ASH Fitness ...
Breaking Medicine News(10 mins):